Correction

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Erik Serrao , Srinivas Odde , Kavya Ramkumar and Nouri Neamati

Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA 90089, USA

author email corresponding author email

Retrovirology 2009, 6:33doi:10.1186/1742-4690-6-33

The electronic version of this article is the complete one and can be found online at: http://www.retrovirology.com/content/6/1/33

Received:	7 April 2009
Accepted:	8 April 2009
Published:	8 April 2009

© 2009 Serrao et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Correction to Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25. Since the recent publication of our article (Neamati, Retrovirology 2009, 6:25), we have noticed an error which we would like to correct and we would like to apologise to the readers for this mistake.

Correction

The structure of BMS-707035 has not been publicly released. In Figure one on page 2 and a discussion on page 5 of our published paper [1], we mistakenly assigned a structure and activity data to BMS-707035. The structure and activity data that we mentioned actually belong to a different compound from the same group. The resistance pattern of BMS-707035 is "overlapping" rather than identical to raltegravir. Please see the following references [2,3] for a detailed description of their development of pyrimidine carboxamides.

References

1. Serrao Erik, Odde Srinivas, Ramkumar Kavya, Neamati Nouri: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

   Retrovirology 2009, 6:25. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text

2. Dicker IB, Samanta HK, Li Z, Hong Y, Tian Y, Banville J, Remillard RR, Walker MA, Langley DR, Krystal M: Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.

   J Biol Chem 2007, 282(43):31186-96. PubMed Abstract | Publisher Full Text

3. Dicker IB, Terry B, Lin Z, Li Z, Bollini S, Samanta HK, Gali V, Walker MA, Krystal MR: Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.

   J Biol Chem 2008, 283(35):23599-609. PubMed Abstract | Publisher Full Text

Have something to say? Post a comment on this article!